uniQure (NASDAQ:QURE) Releases Quarterly Earnings Results, Beats Estimates By $0.37 EPS

uniQure (NASDAQ:QURE) announced its quarterly earnings results on Monday. The biotechnology company reported ($0.56) EPS for the quarter, beating analysts’ consensus estimates of ($0.93) by $0.37, FiscalAI reports. uniQure had a negative return on equity of 373.73% and a negative net margin of 1,492.90%.The company had revenue of $5.57 million during the quarter, compared to analysts’ expectations of $4.84 million.

uniQure Price Performance

uniQure stock opened at $15.63 on Monday. The company has a market capitalization of $973.62 million, a price-to-earnings ratio of -3.56 and a beta of 0.66. The company has a current ratio of 7.12, a quick ratio of 7.12 and a debt-to-equity ratio of 0.23. uniQure has a 12 month low of $7.76 and a 12 month high of $71.50. The stock’s 50 day moving average is $23.46 and its 200-day moving average is $29.80.

Analyst Ratings Changes

A number of equities research analysts recently commented on the stock. Leerink Partners dropped their price objective on shares of uniQure from $68.00 to $60.00 and set an “outperform” rating on the stock in a report on Monday, November 10th. Cantor Fitzgerald reiterated an “overweight” rating on shares of uniQure in a report on Wednesday, January 14th. Wolfe Research began coverage on uniQure in a report on Monday, February 23rd. They issued a “peer perform” rating on the stock. Wall Street Zen downgraded uniQure from a “hold” rating to a “sell” rating in a report on Sunday, January 11th. Finally, Barclays began coverage on uniQure in a research report on Tuesday, January 27th. They issued an “equal weight” rating and a $31.00 target price on the stock. Ten research analysts have rated the stock with a Buy rating, four have assigned a Hold rating and one has issued a Sell rating to the stock. According to data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and a consensus target price of $58.33.

More uniQure News

Here are the key news stories impacting uniQure this week:

• Positive Sentiment: Quarterly results beat expectations: uniQure reported EPS of ($0.56) vs. consensus ($0.93) and revenue of $5.57M vs. ~$4.8M — a modest fundamental beat that reduces near‑term execution concerns. uniQure Announces 2025 Financial Results
• Positive Sentiment: Regulatory engagement on AMT‑130: uniQure held a Type A meeting with the FDA on its Huntington’s disease candidate and plans to seek a follow‑up Type B meeting in Q2‑2026 — an important step if the company moves toward Phase III discussions. Regulatory update on AMT-130
• Positive Sentiment: Bullish options flow suggests speculative interest: market commentary flagged heavy call buying, indicating some traders are positioning for a near‑term rebound or event. No external link
• Neutral Sentiment: Divergent analyst views: multiple firms have trimmed price targets recently, but consensus remains a “Moderate Buy” with a wide spread of estimates — contributing to uncertain near‑term sentiment but reflecting longer‑term upside in some models. No external link
• Negative Sentiment: FDA scrutiny and negative media coverage rattled investors — coverage of critical FDA remarks about a rejected therapy is being cited as the main catalyst for the selloff and increases perceived regulatory risk for uniQure’s pipeline. uniQure down after FDA scrutiny
• Negative Sentiment: Mounting securities‑class action activity: several law firms (DJS, Schall, Kessler Topaz, Rosen, etc.) have filed or are soliciting lead plaintiffs alleging misstatements during a specified class period — this increases legal expense risk and investor uncertainty. DJS Law Group notice
• Negative Sentiment: Insider selling: the CFO sold ~6,217 shares in late Feb (filed with the SEC), which can be interpreted negatively by some investors even though his remaining stake remains large. Insider selling disclosure

Insider Transactions at uniQure

In other news, CFO Christian Klemt sold 6,217 shares of the business’s stock in a transaction dated Wednesday, February 25th. The shares were sold at an average price of $23.86, for a total value of $148,337.62. Following the completion of the sale, the chief financial officer owned 211,513 shares of the company’s stock, valued at approximately $5,046,700.18. The trade was a 2.86% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, Director Robert Gut sold 25,613 shares of the firm’s stock in a transaction dated Monday, January 12th. The stock was sold at an average price of $24.62, for a total transaction of $630,592.06. Following the transaction, the director directly owned 32,342 shares in the company, valued at approximately $796,260.04. This represents a 44.19% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Over the last quarter, insiders have sold 50,598 shares of company stock valued at $1,248,588. Company insiders own 4.79% of the company’s stock.

Institutional Inflows and Outflows

Hedge funds have recently added to or reduced their stakes in the company. State Street Corp raised its stake in uniQure by 123.8% during the 4th quarter. State Street Corp now owns 3,231,043 shares of the biotechnology company’s stock worth $77,319,000 after buying an additional 1,787,033 shares during the period. JPMorgan Chase & Co. raised its position in shares of uniQure by 155.3% during the fourth quarter. JPMorgan Chase & Co. now owns 2,934,626 shares of the biotechnology company’s stock worth $70,226,000 after purchasing an additional 1,785,275 shares during the period. Franklin Resources Inc. lifted its holdings in shares of uniQure by 23.9% in the 3rd quarter. Franklin Resources Inc. now owns 1,988,581 shares of the biotechnology company’s stock worth $116,073,000 after purchasing an additional 383,066 shares in the last quarter. Sofinnova Investments Inc. grew its position in uniQure by 185.5% in the 2nd quarter. Sofinnova Investments Inc. now owns 1,558,356 shares of the biotechnology company’s stock valued at $21,723,000 after purchasing an additional 1,012,585 shares during the period. Finally, MPM Bioimpact LLC bought a new stake in uniQure during the 4th quarter valued at $33,062,000. 78.83% of the stock is owned by institutional investors.

About uniQure

uniQure N.V. is a biotechnology company focused on the development and commercialization of gene therapies for patients with severe medical needs. Using its proprietary adeno‐associated viral (AAV) vector platform, the company designs single‐dose treatments aimed at addressing the underlying genetic causes of disease rather than solely managing symptoms. Its most advanced program, Hemgenix® (etranacogene dezaparvovec), received regulatory approval in the United States and Europe for adult patients with hemophilia B, marking one of the first gene therapies for a bleeding disorder to reach the market.

Beyond hemophilia B, uniQure’s pipeline includes preclinical and clinical-stage candidates targeting rare and debilitating conditions such as aromatic l-amino acid decarboxylase (AADC) deficiency, Huntington’s disease, and Parkinson’s disease.